clinical trial · NCT06963177
A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
Changchun GeneScience Pharmaceutical Co., Ltd.·phase2·recruiting·n = 200
Endometriosis-related PainGenSci048Placebo
brief summary
This study is designed to evaluate the safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain treatment.
started
May 26, 2025
primary completion
May 15, 2028
completion
Jan 6, 2030
last updated
Aug 12, 2025
official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol